Shares of Favrille(FVRL Quote) were among the best-performing health-related stocks Thursday, jumping 33% after the developer of cancer treatments said its FavId product received fast-track status from the Food and Drug Administration.
The treatment is used to combat B-cell follicular non-Hodgkin's lyphoma. FavId is currently being evaluated in a phase III clinical trial. "This decision by the FDA has the potential to save us valuable time in the regulatory approval process, and also serves as an important acknowledgement of the potential for FavId in the treatment of B-cell follicular NHL," the company said. Shares were trading up $1.33 to $5.37.
CryoLife(CRY Quote) surged 20% after the biosurgical device company said the FDA approved its new 10-milliliter disposable syringe for BioGlue surgical adhesive. The BioGlue syringe is already available in the U.S. in 2-milliliter and 5-milliliter volumes. The 10-milliliter syringe, which is already being used in Europe, will be introduced into the U.S. market late in the first quarter, the company said. "The 10ml BioGlue Syringe provides surgeons with an effective adhesive in an easy-to-use, self-contained, disposable syringe, ideally suited for complex cardiovascular surgery procedures," CryoLife said in a statement. Shares were trading up 78 cents to $4.60. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,441.12 | 1,109.18 | 2,206.91 | 35.96 |
Oil *
73.55
|
|
DOWN
10.88
|
UP
1.25
|
UP
5.86
|
DOWN
0.07
|
10 Yr
3.60%
SPDR Gold
111.59
|
|
-0.10%
|
+0.11%
|
+0.27%
|
-0.19%
|
Data delayed 20 minutes |


Connect with TheStreet